SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Jones Ashley R.) "

Sökning: WFRF:(Jones Ashley R.)

  • Resultat 11-20 av 25
  • Föregående 1[2]3Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • van Rheenen, Wouter, et al. (författare)
  • Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
  • 2016
  • Ingår i: Nature Genetics. - 1061-4036 .- 1546-1718. ; 48:9, s. 1043-1048
  • Tidskriftsartikel (refereegranskat)abstract
    • To elucidate the genetic architecture of amyotrophic lateral sclerosis (ALS) and find associated loci, we assembled a custom imputation reference panel from whole-genome-sequenced patients with ALS and matched controls (n = 1,861). Through imputation and mixed-model association analysis in 12,577 cases and 23,475 controls, combined with 2,579 cases and 2,767 controls in an independent replication cohort, we fine-mapped a new risk locus on chromosome 21 and identified C21orf2 as a gene associated with ALS risk. In addition, we identified MOBP and SCFD1 as new associated risk loci. We established evidence of ALS being a complex genetic trait with a polygenic architecture. Furthermore, we estimated the SNP-based heritability at 8.5%, with a distinct and important role for low-frequency variants (frequency 1-10%). This study motivates the interrogation of larger samples with full genome coverage to identify rare causal variants that underpin ALS risk.
  •  
12.
  • Fresard, Laure, et al. (författare)
  • Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts
  • 2019
  • Ingår i: Nature Medicine. - : NATURE PUBLISHING GROUP. - 1078-8956 .- 1546-170X. ; 25:6, s. 911-919
  • Tidskriftsartikel (refereegranskat)abstract
    • It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene(1). The current molecular diagnostic rate is estimated at 50%, with whole-exome sequencing (WES) among the most successful approaches(2-5). For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases(6-8). This includes muscle biopsies from patients with undiagnosed rare muscle disorders(6,9), and cultured fibroblasts from patients with mitochondrial disorders(7). However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5% diagnostic rate, and an additional 16.7% with improved candidate gene resolution.
  •  
13.
  •  
14.
  • Söderström, Pär-Anders, et al. (författare)
  • Spectroscopy of neutron-rich Dy-168,Dy-170 : Yrast band evolution close to the NpNn valence maximum
  • 2010
  • Ingår i: Physical Review C. Nuclear Physics. - : American Physical Society. - 0556-2813 .- 1089-490X. ; 81:3, s. 034310-
  • Tidskriftsartikel (refereegranskat)abstract
    • The yrast sequence of the neutron-rich dysprosium isotope Dy-168 has been studied using multinucleon transfer reactions following collisions between a 460-MeV Se-82 beam and an Er-170 target. The reaction products were identified using the PRISMA magnetic spectrometer and the gamma rays detected using the CLARA HPGe-detector array. The 2(+) and 4(+) members of the previously measured ground-state rotational band of Dy-168 have been confirmed and the yrast band extended up to 10(+). A tentative candidate for the 4(+) -> 2(+) transition in Dy-170 was also identified. The data on these nuclei and on the lighter even-even dysprosium isotopes are interpreted in terms of total Routhian surface calculations and the evolution of collectivity in the vicinity of the proton-neutron valence product maximum is discussed.
  •  
15.
  •  
16.
  • Fu, Yi-Ping, et al. (författare)
  • The 19q12 Bladder Cancer GWAS Signal : Association with Cyclin E Function and Aggressive Disease
  • 2014
  • Ingår i: Cancer Research. - 0008-5472 .- 1538-7445. ; 74:20, s. 5808-5818
  • Tidskriftsartikel (refereegranskat)abstract
    • A genome-wide association study (GWAS) of bladder cancer identified a genetic marker rs8102137 within the 19q12 region as a novel susceptibility variant. This marker is located upstream of the CCNE1 gene, which encodes cyclin E, a cell-cycle protein. We performed genetic fine-mapping analysis of the CCNE1 region using data from two bladder cancer GWAS (5,942 cases and 10,857 controls). We found that the original GWAS marker rs8102137 represents a group of 47 linked SNPs (with r(2) >= 0.7) associated with increased bladder cancer risk. From this group, we selected a functional promoter variant rs7257330, which showed strong allele-specific binding of nuclear proteins in several cell lines. In both GWASs, rs7257330 was associated only with aggressive bladder cancer, with a combined per-allele OR = 1.18 [95% confidence interval (CI), 1.09-1.27, P = 4.67 x 10(-5)] versus OR = 1.01 (95% CI, 0.93-1.10, P = 0.79) for nonaggressive disease, with P = 0.0015 for case-only analysis. Cyclin E protein expression analyzed in 265 bladder tumors was increased in aggressive tumors (P = 0.013) and, independently, with each rs7257330-A risk allele (P-trend = 0.024). Overexpression of recombinant cyclin E in cell lines caused significant acceleration of cell cycle. In conclusion, we defined the 19q12 signal as the first GWAS signal specific for aggressive bladder cancer. Molecular mechanisms of this genetic association may be related to cyclin E overexpression and alteration of cell cycle in carriers of CCNE1 risk variants. In combination with established bladder cancer risk factors and other somatic and germline genetic markers, the CCNE1 variants could be useful for inclusion into bladder cancer risk prediction models.
  •  
17.
  • Kenna, Kevin P., et al. (författare)
  • NEK1 variants confer susceptibility to amyotrophic lateral sclerosis
  • 2016
  • Ingår i: Nature Genetics. - 1061-4036 .- 1546-1718. ; 48:9, s. 1037-1042
  • Tidskriftsartikel (refereegranskat)abstract
    • To identify genetic factors contributing to amyotrophic lateral sclerosis (ALS), we conducted whole-exome analyses of 1,022 index familial ALS (FALS) cases and 7,315 controls. In a new screening strategy, we performed gene-burden analyses trained with established ALS genes and identified a significant association between loss-of-function (LOF) NEK1 variants and FALS risk. Independently, autozygosity mapping for an isolated community in the Netherlands identified a NEK1 p.Arg261 His variant as a candidate risk factor. Replication analyses of sporadic ALS (SALS) cases and independent control cohorts confirmed significant disease association for both p.Arg261 His (10,589 samples analyzed) and NEK1 LOF variants (3,362 samples analyzed). In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity. Our results provide new and important insights into ALS etiopathogenesis and genetic etiology.
  •  
18.
  • Wang, F., et al. (författare)
  • Reinvestigation of the excited states in the proton emitter Lu-151 : Particle-hole excitations across the N = Z=64 subshell
  • 2017
  • Ingår i: Physical Review C. - : American Physical Society. - 2469-9985 .- 2469-9993. ; 96:6
  • Tidskriftsartikel (refereegranskat)abstract
    • The excited states of the proton emitter Lu-151 were reinvestigated in a recoil-decay tagging experiment at the Accelerator Laboratory of the University of Jyvaskyla (JYFL). The level scheme built on the ground state of 151Lu was updated with five new y-ray transitions. Large-scale shell model calculations were carried out in the model space consisting of the neutron and proton orbitals 0g(7/2), Id(5/2), Id(3/2), 2s(1/2), and Oh(1/2) with the optimized monopole interaction in order to interpret the experimental level scheme of Lu-151. It is found that the excitation energies of states above the 27/2(-) and 23/2(+) isomeric levels in Lu-151 can be sensitive to excitations from g(7/2) and d(5/2) to single-particle orbitals above N = Z = 64.
  •  
19.
  • Wang, F., et al. (författare)
  • Spectroscopic factor and proton formation probability for the d3/2 proton emitter 151mLu
  • 2017
  • Ingår i: Physics Letters B. - : Elsevier. - 0370-2693 .- 1873-2445. ; 770, s. 83-87
  • Tidskriftsartikel (refereegranskat)abstract
    • The quenching of the experimental spectroscopic factor for proton emission from the short-lived d3/2 isomeric state in 151mLu was a long-standing problem. In the present work, proton emission from this isomer has been reinvestigated in an experiment at the Accelerator Laboratory of the University of Jyväskylä. The proton-decay energy and half-life of this isomer were measured to be 1295(5) keV and 15.4(8) μs, respectively, in agreement with another recent study. These new experimental data can resolve the discrepancy in the spectroscopic factor calculated using the spherical WKB approximation. Using the R-matrix approach it is found that the proton formation probability indicates no significant hindrance for the proton decay of 151mLu.
  •  
20.
  • O'Brien, John T, et al. (författare)
  • Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
  • 2011
  • Ingår i: Journal of psychopharmacology (Oxford, England). - 1461-7285. ; 25:8, s. 997-1019
  • Forskningsöversikt (refereegranskat)abstract
    • The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A to D, with A having the strongest evidence base (from randomized controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and brain imaging can improve diagnostic accuracy (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for mild to moderate Alzheimer's disease (A) and memantine for moderate to severe Alzheimer's disease (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (Parkinson's disease dementia and dementia with Lewy bodies (DLB)), especially for neuropsychiatric symptoms (A). Cholinesterase inhibitors and memantine can produce cognitive improvements in DLB (A). There is no clear evidence that any intervention can prevent or delay the onset of dementia. Although the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition are in progress. Although results of pivotal studies are awaited, results to date have been equivocal and no disease-modifying agents are either licensed or can be currently recommended for clinical use.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 25
  • Föregående 1[2]3Nästa
Typ av publikation
tidskriftsartikel (21)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (25)
Författare/redaktör
Al-Chalabi, Ammar (5)
Liu, Z. (4)
Andersen, Peter M. (4)
Shatunov, Aleksey (4)
Jones, Ashley R. (4)
Uitterlinden, Andre ... (4)
visa fler...
Shaw, Christopher E. (4)
Pietri, S. (4)
Gelletly, W. (4)
Ashley, S. F. (4)
O'Donovan, MC (4)
Owen, MJ (4)
Sullivan, PF (3)
Crane, Jeffrey D. (3)
Stassun, Keivan (3)
Teske, Johanna (3)
Kogevinas, Manolis (3)
Kogevinas, M (3)
Cichon, Sven (3)
Foroud, Tatiana M. (3)
Hardy, John (3)
Montgomery, Grant W. (3)
Noethen, Markus M. (3)
Rietschel, Marcella (3)
Martin, Nicholas G. (3)
Medland, Sarah E. (3)
Uitterlinden, AG (3)
Foroud, TM (3)
Medland, SE (3)
Martin, NG (3)
Nothen, MM (3)
Montgomery, GW (3)
Knowles, JA (3)
van Rheenen, Wouter (3)
Veldink, Jan H. (3)
Rouleau, Guy A. (3)
van den Berg, Leonar ... (3)
Podolyak, Zs. (3)
Metspalu, A (3)
Metspalu, Andres (3)
Herms, S. (3)
Hoffmann, P. (3)
Forstner, AJ (3)
Forstner, Andreas J (3)
Herms, Stefan (3)
Hoffmann, Per (3)
Gill, Michael (3)
Gill, M. (3)
Escott-Price, V (3)
Gordon, SD (3)
visa färre...
Lärosäte
Umeå universitet (9)
Uppsala universitet (5)
Karolinska Institutet (5)
Lunds universitet (4)
Göteborgs universitet (3)
Stockholms universitet (3)
visa fler...
Kungliga Tekniska Högskolan (2)
Chalmers tekniska högskola (2)
visa färre...
Språk
Engelska (25)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (13)
Medicin och hälsovetenskap (10)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy